Targeted enzyme prodrug therapy
First Claim
Patent Images
1. A pharmaceutical composition comprising a targeted enzyme (TE) and a pharmaceutically acceptable carrier, excipient or diluent, said TE exhibiting a catalytic activity that converts a prodrug to a product and comprising:
- a) a substrate recognition site; and
b) a targeting site that binds a target;
wherein i) the targeting site comprises a variant sequence that is derived from a variation-tolerant sequence of a corresponding pre-targeted enzyme that does not bind the target, ii) the target is bound by the TE but not by the pre-targeted enzyme under like conditions; and
iii) the target is not an isolated monoclonal antibody.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention provides targeted enzymes that bind to targets better than the corresponding pre-targeted enzymes bind the target under like conditions, methods of making targeted enzymes, methods of using targeted enzymes to treat diseases, and pharmaceutical compositions comprising targeted enzymes.
31 Citations
29 Claims
-
1. A pharmaceutical composition comprising a targeted enzyme (TE) and a pharmaceutically acceptable carrier, excipient or diluent, said TE exhibiting a catalytic activity that converts a prodrug to a product and comprising:
-
a) a substrate recognition site; and
b) a targeting site that binds a target;
wherein i) the targeting site comprises a variant sequence that is derived from a variation-tolerant sequence of a corresponding pre-targeted enzyme that does not bind the target, ii) the target is bound by the TE but not by the pre-targeted enzyme under like conditions; and
iii) the target is not an isolated monoclonal antibody. - View Dependent Claims (13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)
-
-
2. A targeted enzyme exhibiting a catalytic activity that converts a prodrug into a product, comprising:
-
a) a substrate recognition site;
b) a first targeting site that binds a first target; and
c) a second targeting site that binds a second target, wherein i) each targeting site comprises a variant sequence derived from variation-tolerant sequences of a corresponding pre-targeted enzyme, and ii) the affinity of the targeted enzyme for the first and second target is greater than the affinity of the pre-targeted enzyme for the first and second target under like conditions. - View Dependent Claims (3, 4, 5, 6)
-
-
7. A targeted enzyme exhibiting a catalytic activity that converts a prodrug to a product, comprising:
-
a) a substrate recognition site; and
b) a targeting site that binds a target, wherein i) the targeting site comprises two variant sequences derived from variation-tolerant sequences of a corresponding pre-targeted enzyme, ii) the affinity of the targeted enzyme for the target is greater than the affinity of the pre-targeted enzyme for the target under like conditions; and
iii) the target is not an isolated monoclonal antibody.
-
-
8. A targeted enzyme exhibiting a catalytic activity that converts a prodrug to a product, comprising:
-
a) a substrate recognition site; and
b) a targeting site that binds a target;
wherein i) the targeting site comprises three variant sequences, wherein each of the variant sequences is derived from variation-tolerant sequences of a corresponding pre-targeted enzyme; and
ii) the affinity of the targeted enzyme for the target is greater than the affinity of the pre-targeted enzyme for the target under like conditions.
-
-
9. A targeted β
- -lactamase enzyme exhibiting a catalytic activity that converts a prodrug to a product, comprising;
a) a substrate recognition site;
b) a first targeting site that binds a first target;
c) a second targeting site that binds a second target; and
d) a sequence KTXS at its substrate recognition site, wherein i) each targeting site comprises a variant sequence derived from a variation-tolerant sequence of a corresponding pre-targeted enzyme, and ii) the affinity of the targeted enzyme for the first and second target is greater than the affinity of the pre-targeted enzyme for the first and second target under like conditions.
- -lactamase enzyme exhibiting a catalytic activity that converts a prodrug to a product, comprising;
-
10. A targeted β
- -lactamase enzyme exhibiting a catalytic activity that converts a prodrug to a product, comprising;
a) a prodrug recognition site;
b) a targeting site that binds a target, and c) a sequence KTXS at its substrate recognition site, wherein i) the targeting site comprises three variant sequences, wherein each of the variant sequences is derived from variation-tolerant sequences of a corresponding pre-targeted β
-lactamase enzyme; and
ii) the affinity of the targeted β
-lactamase enzyme for the target is greater than the affinity of the pre-targeted β
-lactamase enzyme for the target under like conditions.
- -lactamase enzyme exhibiting a catalytic activity that converts a prodrug to a product, comprising;
-
11. A targeted β
- -lactamase enzyme exhibiting a catalytic activity that converts a prodrug to a product, comprising;
a) a substrate recognition site;
b) a targeting site that binds a target, and c) a sequence KTXS at its substrate recognition site, wherein i) the targeting site comprises two variant sequences, wherein each of the variant sequences is derived from variation-tolerant sequences of a corresponding pre-targeted β
-lactamase enzyme,ii) the affinity of the targeted β
-lactamase enzyme for the target is greater than the affinity of the pre-targeted β
-lactamase enzyme for the target, andiii) the target is not an isolated monoclonal antibody.
- -lactamase enzyme exhibiting a catalytic activity that converts a prodrug to a product, comprising;
-
12. A pharmaceutical composition comprising a targeted β
- -lactamase enzyme and a pharmaceutically acceptable carrier, excipient, or diluent, said enzyme exhibiting a catalytic activity that converts a prodrug to a product and comprising;
a) a substrate recognition site;
b) a targeting site that binds a target; and
c) a sequence KTXS at its substrate recognition site, wherein i) the targeting site comprises a variant sequence that is derived from a variation-tolerant sequence of a corresponding pre-targeted enzyme that does not bind the target, ii) the target is bound by the targeted β
-lactamase enzyme but not by the pre-targeted β
-lactamase enzyme under like conditions, andiii) the target is not an isolated monoclonal antibody.
- -lactamase enzyme and a pharmaceutically acceptable carrier, excipient, or diluent, said enzyme exhibiting a catalytic activity that converts a prodrug to a product and comprising;
Specification